RxDoctor Payments Data

Cristen Crain, NP

Family · Baton Rouge, LANPI 1598190837

Payments from drug & device makers

$2,601in general payments, 2019–2025

Across 134 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$456
  • Novo Nordisk$307
  • Boehringer Ingelheim$301
  • AstraZeneca$249
  • Abbott$234
  • AbbVie$152
  • plus $902 from 19 others

What the payments were for

  • Food & beverage$2,601100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,601 in reported general payments places this provider in the 80th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$3,355
Medicare patients
15
Services billed
48

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide16$14,065
Albuterol Sulfate HfaAlbuterol Sulfate16$564
Fluticasone Propionate21$223
Omeprazole13$207
Amlodipine Besylate35$177
Zolpidem Tartrate13$158
Metformin Hcl ErMetformin Hcl11$140
Gabapentin23$136
Atorvastatin Calcium16$30
Meloxicam16$24

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$307$14,06516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,610 family providers in Louisiana.

Other family in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →